Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome

Norman B. Gaylis; Angela Ritter; Scott A. Kelly; Nader Z. Pourhassan; Meenakshi Tiwary; Jonah B. Sacha; Scott G. Hansen; Christopher Recknor; Otto O. Yang

doi:10.1093/cid/ciac226

Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome

Norman B. Gaylis, Angela Ritter, Scott A. Kelly, Nader Z. Pourhassan, Meenakshi Tiwary, Jonah B. Sacha, Scott G. Hansen, Christopher Recknor, Otto O. Yang

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

In an exploratory trial treating "long COVID"with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab. Clinical Trials Registration. NCT04678830.

Original language	English (US)
Pages (from-to)	1232-1234
Number of pages	3
Journal	Clinical Infectious Diseases
Volume	75
Issue number	7
DOIs	https://doi.org/10.1093/cid/ciac226
State	Published - Oct 1 2022

Keywords

CCR5
immunosuppression
leronlimab
long COVID

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/ciac226

Cite this

@article{b9f581bfb41f4a6093c4b08aaa8b9db0,

title = "Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome",

abstract = "In an exploratory trial treating {"}long COVID{"}with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab. Clinical Trials Registration. NCT04678830.",

keywords = "CCR5, immunosuppression, leronlimab, long COVID",

author = "Gaylis, {Norman B.} and Angela Ritter and Kelly, {Scott A.} and Pourhassan, {Nader Z.} and Meenakshi Tiwary and Sacha, {Jonah B.} and Hansen, {Scott G.} and Christopher Recknor and Yang, {Otto O.}",

year = "2022",

month = oct,

day = "1",

doi = "10.1093/cid/ciac226",

language = "English (US)",

volume = "75",

pages = "1232--1234",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "7",

}

TY - JOUR

T1 - Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome

AU - Gaylis, Norman B.

AU - Ritter, Angela

AU - Kelly, Scott A.

AU - Pourhassan, Nader Z.

AU - Tiwary, Meenakshi

AU - Sacha, Jonah B.

AU - Hansen, Scott G.

AU - Recknor, Christopher

AU - Yang, Otto O.

PY - 2022/10/1

Y1 - 2022/10/1

N2 - In an exploratory trial treating "long COVID"with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab. Clinical Trials Registration. NCT04678830.

AB - In an exploratory trial treating "long COVID"with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab. Clinical Trials Registration. NCT04678830.

KW - CCR5

KW - immunosuppression

KW - leronlimab

KW - long COVID

UR - http://www.scopus.com/inward/record.url?scp=85141518369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85141518369&partnerID=8YFLogxK

U2 - 10.1093/cid/ciac226

DO - 10.1093/cid/ciac226

M3 - Article

AN - SCOPUS:85141518369

SN - 1058-4838

VL - 75

SP - 1232

EP - 1234

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 7

ER -

Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this